A Monoclonal Antibody against p53 Cross-Reacts with Processing Bodies by Thomas, María Gabriela et al.
A Monoclonal Antibody against p53 Cross-Reacts with
Processing Bodies







1Instituto Leloir Av. Patricias Argentinas Buenos Aires, Argentina, 2IIBBA-CONICET, Buenos Aires, Argentina, 3Facultad de Ciencias Exactas y Naturales, University of
Buenos Aires, Argentina
Abstract
The p53 tumor suppressor protein is an important regulator of cell proliferation and apoptosis. p53 can be found in the
nucleus and in the cytosol, and the subcellular location is key to control p53 function. In this work, we found that a
widely used monoclonal antibody against p53, termed Pab 1801 (Pan antibody 1801) yields a remarkable punctate
signal in the cytoplasm of several cell lines of human origin. Surprisingly, these puncta were also observed in two
independent p53-null cell lines. Moreover, the foci stained with the Pab 1801 were present in rat cells, although Pab
1801 recognizes an epitope that is not conserved in rodent p53. In contrast, the Pab 1801 nuclear staining
corresponded to genuine p53, as it was upregulated by p53-stimulating drugs and absent in p53-null cells. We
identified the Pab 1801 cytoplasmic puncta as P Bodies (PBs), which are involved in mRNA regulation. We found that, in
several cell lines, including U2OS, WI38, SK-N-SH and HCT116, the Pab 1801 puncta strictly colocalize with PBs identified
with specific antibodies against the PB components Hedls, Dcp1a, Xrn1 or Rck/p54. PBs are highly dynamic and
accordingly, the Pab 1801 puncta vanished when PBs dissolved upon treatment with cycloheximide, a drug that causes
polysome stabilization and PB disruption. In addition, the knockdown of specific PB components that affect PB integrity
simultaneously caused PB dissolution and the disappearance of the Pab 1801 puncta. Our results reveal a strong cross-
reactivity of the Pab 1801 with unknown PB component(s). This was observed upon distinct immunostaining protocols,
thus meaning a major limitation on the use of this antibody for p53 imaging in the cytoplasm of most cell types of
human or rodent origin.
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Introduction
The p53 tumor suppressor is a key factor involved in the cellular
response to the accumulation of damaged DNA and other cell
insults like hypoxia, oncogene expression, nutrient deprivation and
ribosome dysfunction [1]. p53 transactivates a number of genes
with a variety of functions including cell cycle arrest, apoptosis and
metabolism regulation, among others [1]. In addition, p53 has
transcription-independent functions that depend on its localization
in the cytoplasm, where p53 modulates apoptosis and autophagy
[2]. While the pro-apoptotic role of cytoplasmic p53 was linked to
its recruitment to the mitochondria [2,3], several groups have
shown that cytoplasmic p53 is not limited to this organelle. Strong
cytoplasmic p53 retention was reported in neuroblastoma cells and
other cell lines, including human fibroblasts upon endoplasmic
reticulum stress [4,5,6,7,8,9,10]. A number of specific proteins that
interact with p53 in the cytoplasm precluding its nuclear import
and thus neutralizing p53-dependent transcriptional activation
were described by several groups [4,5,6,7,8,9,10]. In line with this,
discrete p53 cytoplasmic aggregates that may represent sites for
p53 storage were described under a variety of conditions [5,6,7,9].
In this work, we used several antibodies to visualize the
subcellular distribution of p53 in several cell lines exposed to
different stimuli. We found that a particular monoclonal antibody,
termed Pantropic antibody 1801 (Pab 1801), yields a strongly
punctate signal in the cytoplasm of several human cell lines.
Strikingly, these foci are also present in p53-negative cells and in rat
cells, which lack the p53 epitope that is specifically recognized by
the Pab 1801. Further analysis clearly indicated that the Pab 1801-
positive foci colocalize with P bodies, which are conserved
cytoplasmic aggregates of RNPs involved in mRNA storage,
silencing and/or decay (reviewed in ref. [11]). PBs are dynamic
and we found that the Pab 1801 punctate signal vanishes upon PB
dissolution. Our results unveil a strong cross-reactivity of the Pab
1801 with PB components, upon a variety of staining conditions,
thus indicating a major limitation of this widely used antibody for
p53 imaging in most cell types.
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The Pab 1801 Against p53 Yields a Granular Cytoplasmic
Signal
We immunostained distinct cell lines, specifically U2OS, WI38,
SK-N-SH and HCT116, with a rabbit polyclonal antibody termed
FL 393, and with a number of monoclonal antibodies against p53,
namely Pab 1801, Pab 240, Pab 421 and Pab DO1 (see materials
and methods), all them widely used in the literature
[6,7,8,9,12,13,14]. Cells were fixed in PFA 4%, permeabilized
and stained as indicated in material and methods. In all the cell
lines tested, the Pab 1801 showed a punctate pattern with granules
of about 0.5 mm in diameter, quite homogenously dispersed in the
cytoplasm (Figure 1A). This staining pattern is quite similar to that
previously described by Moll et al. in SK-N-SH neuroblastoma
cells using a different staining procedure that includes non-
aqueous fixation [6,7]. The remaining antibodies against p53
display the faint nuclear staining typically observed under resting
conditions, and showed no significant signal in the cytosol (Figure 1
A and B).
To investigate whether the distinct pattern of the Pab 1801 is
affected by increased p53 levels, we induce p53 in WI38 cells with
daunorubicin, a DNA- damaging drug, or with actinomycin D,
which does not induce DNA-damage but nevertheless causes p53
accumulation [15], and stained the cells with the Pab 1801 or the
Pab DO1. As expected, we found that the p53 nuclear signal
increased in both cases (Figure 1B and data not shown). In
contrast, the cytoplasmic puncta stained by the Pab 1801
remained unaltered. They did not change in number (between 8
and 12 per cell in all cases), size (about 0,5 mm in all conditions) or
brightness (Figure 1B and data not shown), indicating that these
structures are not affected when p53 levels are upregulated. Pab
DO1 staining was exclusively nuclear upon drug treatment, and
no cytosolic signal was observed despite the dramatic increase on
p53 levels (Figure 1 B).
The Decay of p53 Upon Translation Inhibition does not
Correlate with a Decay of the Cytoplasmic Puncta
p53 decays rapidly upon translation blockage. Then, we sought
to investigate whether the 1801-positive puncta decay upon
treatment of U2OS cells with two translation inhibitors,
cycloheximide (CHX) and puromycin (PURO). In parallel, we
evaluated p53 levels by western blotting using the DO1 antibody,
one of the most used antibodies for p53 immunoblotting. As
expected, we found that p53 decayed rapidly upon inhibition of
protein synthesis with cycloheximide or puromycin. In both cases,
p53 levels were reduced to 60% relative to basal levels after 1 hour
treatment, to half after three hours, and to one third upon 6 hours
(Figure 2A). Strikingly, the Pab 1801 cytoplasmic puncta showed a
quite distinct behaviour. They vanished upon exposure to
cycloheximide, but were unaffected by puromycin. The propor-
tion of cells with visible Pab 1801 puncta were reduced from 96%
to 5% upon 6 h of cycloheximide treatment, but remained high
(98%) upon exposure to puromycin (Figure 2B), although in both
cases p53 levels were significantly reduced. This strongly suggests
that in addition to nuclear p53, the Pab 1801 recognizes cellular
components distinct from p53 and present in cytoplasmic foci.
The Pab 1801-puncta are Present in p53-negative Cells
Then, we assessed the Pab 1801 staining in p53-negative cell
lines. We used p532/2 HCT116 cells, where both p53 alleles are
disrupted by homologous recombination [16]. Strikingly, we found
that the Pab 1801 recognized cytoplasmic puncta, as in p53+/+
HCT116 cells (Figure 3A), that were similar to those present in
other cell lines (see Figure 1A). To ascertain that these cells lack
p53, we exposed p53+/+ and p532/2 HCT116 cells to
daunorubicin. As expected, we found that the p53 nuclear signal
increased in p53+/+ HCT116 but not in p532/2 cells
(Figure 3A). As above, the cytoplasmic puncta stained by the
Pab 1801 remained unaltered upon DNA damage induction
(Figure 3A). Finally, the DO1 antibody did not detect any cytosolic
puncta in these cells, exposed or not to DNA damage agents,
which upregulated p53 strongly (Figure 3B). The Pab 1801 also
stained cytoplasmic foci in p53-negative H1299 cells, which have a
homozygous partial deletion of the p53 gene that precludes p53
expression (Figure 3C) ([17]. Also see detailed description in
ATCC CRL-5803 web page (http://www.atcc.org/
ATCCAdvancedCatalogSearch/ProductDetails/tabid/452/
Default.aspx?ATCCNum=CRL-5803&Template=cellBiology).
Moreover, as described for p53-positive cells (see Figure 2B), the
Pab 1801 puncta detected in p53-negative H1299 cells dissolved
upon treatment with cycloheximide, and remained unaltered upon
exposure to puromycin (Figure 3C). Altogether, these observations
indicate that the Pab 1801 cross-react with cytoplasmic structures
that apparently do not contain p53.
The Pab 1801 recognizes an epitope at the N-terminal region of
human p53 and does not recognize rodent p53 [18,19], as the
amino acid sequence is not conserved (Figure 3D). Then, we
sought to investigate whether the Pab 1801-positive cytoplasmic
puncta were as well present in rat cells. We stained primary
cultures of rat hippocampal neurons with the Pab 1801 and found
numerous foci in the soma and dendrites (Figure 3E). As in human
cell lines (Figures 1A, 1B, 3A, 3B), the DO1 antibody did not stain
any cytoplasmic puncta in rat neurons. Collectively, these
observations indicate that in addition to p53, the Pab 1801
recognizes an unknown cellular component that is conserved in
human and rat cells.
Figure 1. The Pab 1801 yields a cytoplasmic punctate pattern.
U2OS, WI38, SK-N-SH, and HCT116 cells were fixed in PFA, permeabi-
lized in Triton 0.1% and immunostained with the indicated antibodies
against p53 as indicated in Materials and Methods. A, Under resting
conditions, the Pab 1801 showed a cytoplasmic granular pattern,
whereas the FL 393, the Pab 240, the Pab 421 and the Pab DO1
antibodies yielded a faint nuclear signal. B, WI38 cells were treated with
daunorubicin or actinomycin D, and immunostained with the indicated
antibodies. A strong p53 nuclear signal was observed in all cases. The
Pab 1801 punctate signal in the cytoplasm remained unaltered. Bar,
10 mm.
doi:10.1371/journal.pone.0036447.g001
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The differential sensitivity of the Pab 1801 puncta to
cycloheximide or puromycin, two strong translational inhibitors,
suggests that they are related to mRNA silencing foci. Briefly,
mRNA silencing foci are cytoplasmic accretions of silenced mRNPs
that exchange mRNA with the cytosol and translating polysomes.
The so-called processing bodies (PBs) and stress granules (SGs) are
the two main silencing foci described to date. Both PBs and SGs
dissolve when polysomes are stabilized by cycloheximide, and
remain unaffected or enhanced when polysomes are disrupted by
puromycin, as a consequence of the rapid shuttling of mRNAs
between the polysomes and the silencing foci (reviewed in
[11,20,21]). Thus, the dissolution of Pab 1801 puncta upon
polysome stabilization by cycloheximide, and their resistance to
polysome breakdown by puromycin correlate with the behaviour
of PBs and SGs. Then, we sought to investigate whether the Pab
1801-stained puncta colocalize with these mRNA silencing foci.
First, we simultaneously stained p53+/+ or p532/2 cells with the
Pab 1801 and commercial antibodies that specifically recognize a
number of accepted PB markers: decapping enzyme 1a (Dcp1a),
Rck/p54, Hedls and exoribonuclease enzyme 1 (Xrn1). We found
that in all cases, 100% of the Pab 1801-positive puncta contained
all the PB components tested (Figure 4). Conversely, all the PBs
identified by Dcp1a, Rck/p54 or Hedls were also recognized by
the Pab 1801 (Figure 4). The Xrn1 foci showed a slightly different
behaviour, and the smallest Xrn1 foci (arrows) were not recognized
by the Pab 1801, suggesting that this anti-p53 antibody does not
cross-react with Xrn1, but rather with some other protein that
concentrates in the largest PBs. Additionally supporting the
identification of the 1801-puncta as PBs, we found that they show
the same response upon polysome stabilization. The Pab 1801 foci
and the PBs vanished simultaneously when cells were exposed to
cycloheximide, whereas translation inhibition by puromycin
elicited no effect (Figure 5 and see also figure 2 above).
To investigate whether the Pab 1801 recognizes SGs, we
exposed the cells to thapsigargin, a known inductor of ER-stress
(Figure 6). SGs were visualized by immunostaining of the SG
components Staufen or TIA-1. As expected [22,23], we found that
thapsigargin triggers SG formation in 80 to 100% of the cells. We
simultaneously stained these cells with the Pab 1801, and found
that in most cases the Pab 1801 puncta were adjacent to the SGs
recognized by either Staufen or TIA-1 (Figure 6). This association
with SGs is typical of PBs and indeed, simultaneous staining of the
PB marker Hedls revealed that the Pab 1801 puncta overlap with
PBs also under stress conditions. Similar results were obtained
upon SG induction by arsenite treatment, a known inducer of
oxidative stress (data not shown).
To further assess the colocalization of the 1801 puncta with PBs,
we sought to induce PB formation. Among several described
strategies that enhance the number of PBs like: c-Jun induction by
Figure 2. p53 decay upon translation inhibition does not correlate with Pab 1801 puncta disappearance. U2OS cells were treated with
cycloheximide (CHX) or puromycin (PURO) during 1, 3, or 6 hs. C, control. A, western blot with the Pab DO1. Duplicates of two-fold dilutions from
each treatment were loaded. p53 levels were determined and normalized using beta-actin as loading control. Error bars, standard deviation. p53
decay was comparable upon protein synthesis inhibition by cycloheximide or puromycin. B, Cells were stained with the Pab 1801. Two representative
cells upon 6 hs-treatment are shown. The percentage of cells with punctate Pab 1801 signal was evaluated in 100 cells from duplicate stainings for
each treatment at the indicated time points. The Pab 1801 puncta vanished upon cycloheximide treatment and remained unaffected upon
puromycin exposure. Bar, 10 mm.
doi:10.1371/journal.pone.0036447.g002
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polysome disassembly [11] and overexpression of translational
repressors [26,27,28], we chose the last two approaches. First we
used different combinations of arsenite and puromycin to
gradually enhance PB formation [11]. As expected, we found
that the number of PBs per cell and their size increased gradually
with the strength of treatment, and induced PBs were stained with
the Pab 1801 in all cases (Figure 7A). Untreated cells had an
average of 4 Pab 1801 puncta per cell, and this number increased
to 14 Pab 1801 puncta per cell upon PB induction. Moreover, the
size of both the Dcp1a-foci and Pab 1801, which strictly
colocalized, increased at the same rate and in a dose-dependend
effect (Figure 7B).
Second, we overexpressed a translational repressor, a manip-
ulation known to enhance the number of PBs [26,27,28]. We
transfect cells with the translational repressor Smaug1, that
dramatically induce PBs [27]. We found that the average number
of 1801 puncta per cell increased from 5 to 55, and in all cases
they were stained with PB markers (Figure 7C). In addition, foci
size in transfected cells was more than twice that in neighbouring
non-transfected cells, as evaluated for both 1801 and Rck/p54
(Figure 7C).
Next, we assessed whether distinct preparations of Pab 1801
from other sources behaved similarly. We stained two p53-positive
cell lines and two p53 -negative cell lines with Pab 1801 from a
commercial source (see Materials and Methods), and found that
this antibody preparation also stained cytoplasmic puncta. As with
the domestic preparation, the Pab 1801 puncta coincided with PBs
stained with Dcp1a, Rck/p54 and Hedls. In summary, two
independent preparations of Pab 1801 showed a strong staining of
PBs in both p53+/+ and 2/2 cells (Figure 8 A and B).
Finally, we investigated whether distinct procedures affect the
outcome of the immunostaining. We treated live U2OS cells with
methanol-acetone, a non-aqueous fixation previously reported to
yield cytoplasmic puncta upon 1801 staining [6,7], as indicated in
materials and methods. We found that the Pab 1801 also stained
PBs upon this procedure (Figure 9B). A stronger fixation with
methanol-acetone at 220uC also rendered preparations where
PBs were strongly recognized by the Pab 1801 (Figure 9C). Finally,
we assessed a procedure known to eliminate most cytosolic
components, which is based on treatment of live cells with non-
ionic detergents [22,29]. We treated U2OS cells with 0.1% Triton
X-100 during 5 or 10 minutes prior to fixation with PFA 4%, as
indicated in materials and methods. We found that this treatment
did not affect the cross-reaction of the Pab1801 with PBs
(Figure 9D, TX100 and Figure 10A, control). Collectively, these
observations indicate that the Pab 1801 stains PBs in several cell
types under a variety of conditions.
The Knockdown of Structural PB Components Provoked
the Dissolution of the Pab 1801 Puncta
To further demonstrate the cross-reactivity of the 1801 antibody
with PBs, we challenged PB integrity by several strategies. First, we
assessed the effect of RNase digestion, a treatment that dissolves
PBs [30]. We treated U2OS cells as indicated in materials and
methods and, as expected, we found that RNAse treatment greatly
reduced the number of cells with PBs from 75% to 40%. The Pab
1801 dotted signal was similarly affected (Figure 10A). In addition,
the size of the remaining foci was reduced to less than half in
comparison with that in control cells (Figure 10A).
Figure 3. Pab 1801 puncta are present in p53-null cells. A, B,
p53+/+ or p532/2 HCT116 cells were treated with daunorubicin and
immunostained with the Pab 1801 (A) or the Pab DO1 (B). With both
antibodies, a nuclear signal is observed upon stimulation of p53+/+
cells but not p532/2 cells. Pab 1801-positive puncta are always present
in p53+/+ and p532/2 cells independently of p53 levels. C, p53-null
H1299 cells were treated with the indicated drugs and stained with the
Pab 1801. The Pab 1801 puncta disappeared upon exposure to
cycloheximide and remained unaltered after puromycin treatment. The
percentage of cells with punctate Pab 1801 signal was evaluated in 100
cells from duplicate stainings for each treatment. Bar, 10 mm. D,
alignment of human and rat p53 N-terminus including the Pab 1801
epitope (grey box). The 10-aa epitope is absent in the rat sequence. E,
Hippocampal rat neurons were prepared as described [27] and stained
with the Pab 1801 or the Pab DO1. A merge of the immunofluorescence
and the phase contrast images is shown. Pab 1801-positive puncta are
detected in cell soma and dendrites. Bars, whole cells, 10 mm;
magnifications, 1 mm.
doi:10.1371/journal.pone.0036447.g003
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immunostained with Pab 1801 and antibodies specific for the PB components Dcp1a, Rck/p54, Hedls or Xrn1. In all cases, all the cytoplasmic foci
recognized by the Pab 1801 were also recognized by the antibodies against PB markers. Bars, whole cells, 10 mm; magnifications, 1 mm.
doi:10.1371/journal.pone.0036447.g004
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molecules required for PB assembly. We treated U2OS and SK-N-
SH cells with small interfering RNA (siRNA) against Hedls, Rck/
p54 or 4ET (eIF4E-Transporter), as previously described [23,27].
The knockdown of these molecules was monitored by western
blotting or RT-PCR. In all cases, expression levels was reduced to
less than 15% relative to control values (not shown, see also ref
[27]). Then, we visualized PBs by staining of Dcp1a or Hedls
(Figure 10B). As reported before [23,27], we found a significant
reduction in the number of cells containing visible PBs after
knockdown of each one of these PB components. We found that
80 to 85% of the cells treated with the non-targeting siRNA (siNT)
contained PBs, and this value was reduced to less than 15% upon
knockdown of Hedls, Rck/p54 or 4ET (Figure 10B). Strikingly,
paralleling PB disappearance, the dotted cytoplasmic Pab 1801
signal vanished upon knockdown of each one of these PB
components. In all cases, the Pab 1801 puncta were detected
only when PBs were visible, and showed strict colocalization with
Dcp1a in both U2OS and SK-N-SH cells (Figure 10B). Collec-
tively, these results indicate that the Pab 1801-positive puncta
colocalize with PBs identified by several markers, and vanished
when PBs are no longer present.
PBs contain hundreds of non-related molecules, most of them
RNA-binding proteins involved in different functions [11,20]. In
western blot assays, we found that the Pab 1801 antibody
recognizes multiple bands in addition to p53 (Figure S1). These
bands of around 75, 60, 36, 33 and 30 kDa were present in two
p53-negative cell lines, and in their corresponding p53-positive
counterparts. We were unable to isolate these proteins by
immunoprecipitation, and therefore, whether they represent the
PB component recognized by the Pab 1801 remains unknown.
Having demonstrated that the Pab 1801 recognize cytoplasmic
puncta in rat neurons (Figure 3) – an organism were the Pab
1801 does not recognize p53 – we assessed the cross-reactivity of
the Pab 1801 with PBs in Drosophila cells. We used S2R+ cells,
where PBs can be visualized by the same markers as in
mammalian cells [11,29,31]. We found that Drosophila PBs,
recognized by Ge-1/Hedls were not recognized by Pab 1801,
which did not reveal any cytoplasmic puncta (Figure 11A). This
indicates that the PB component(s) recognized by the Pab 1801 is
not conserved in flies.
PBs are present in all cell types, but in contrast to cell lines,
where PBs are quite homogenous, a number of different PBs
with distinct composition were reported to be present in neurons,
particularly in dendrites (reviewed in [11]). Given that the Pab
1801 puncta are detected in cultured rat neurons (Figure 3), we
used these cells to interrogate which components are present in
the PBs recognized by the Pab 1801. We found that 38% of the
Pab 1801 puncta colocalize with PBs containing Hedls
(Figure 11B), suggesting that a component of these PBs, but
unlikely Hedls, is cross-reacting with the Pab 1801. Xrn1 label a
distinct subset of neuronal PBs [32], and we found that they are
not stained by the Pab 1801 (Figure 11C). In neurons, Dcp1a
and Rck/p54 label a distinct set of PBs [32], and we found that
the Pab 1801 puncta did not colocalize with any of these two
markers (Figure 11C). As above, the Pab DO1 yielded no signal
above background staining (Fig 11C).
While the identification of the cross-reactive protein(s) will
demand intensive work, we have so far ruled out cross-reactivity
of the Pab 1801 with a number of PB components, namely
Dcp1a, Dcp1b, Rck/p54, Dcp2, and 4ET by means of a
transient-transfection approach (see supporting information S1,
supporting materials and methods S1 and figure S2).
Altogether, these observations indicate that Pab 1801 recog-
nize a PB component different from Dcp1a; Dcp1b; Dcp2, Rck/
p54, Xrn1, 4ET and Hedls, and that is conserved in human and
rodents, but not in Drosophila.
Figure 5. PBs and Pab 1801-positive puncta simultaneously
dissolve upon polysome stabilization. U2OS cells were treated
with CHX or PURO during one hour, and immunostained with the
indicated antibodies. The Pab 1801 punctate signal vanished together
with the PBs upon cycloheximide treatment. Both foci remained intact
upon exposure to puromycin. The percentage of cells with PBs
simultaneous stained with Dcp1a and Pab 1801 was evaluated in 100
cells from duplicate experiments for each treatment. The Pab 1801 foci
were never observed free of Dcp1a, and PBs were always stained with
the Pab 1801. Bar, 10 mm.
doi:10.1371/journal.pone.0036447.g005
Figure 6. Pab 1801 puncta colocalizes with PBs under stress
conditions. WI38 or U2OS cells were treated with 1 mM thapsigargin
during one hour, and immunostained with the indicated antibodies.
The Pab 1801 puncta do not colocalize with SGs, but are adjacent to
them and always overlap with PBs, as in Figures 4 and 5. Bars, whole
cells, 10 mm; magnifications, 1 mm.
doi:10.1371/journal.pone.0036447.g006
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We have combined pharmacological and siRNA approaches
with imaging analysis to reveal a previously unknown cross-
reaction of the Pab 1801 with PB component(s). Strikingly, these
Pab 1801-positive cytoplasmic puncta do not contain p53, since
they are also present in two independent p53-negative cell lines. In
addition, Pab 1801-cytoplasmic puncta were observed in rat cells,
despite the fact that rat p53 lacks the Pab 1801-specific epitope
[18]. In contrast, the Pab 1801 nuclear staining corresponds to
genuine p53, as it is upregulated by p53-activating stimuli and
absent in p53-null cells.
We also demonstrated that the Pab 1801 puncta are the result of
a cross-reaction of this monoclonal antibody with a yet uniden-
tified PB component, This crossreactivity was observed upon a
variety of immunostaining strategies, including procedures previ-
ously used by several authors to show the presence of p53
cytoplasmic dots in neuroblastoma cells [6,7].While the cross-
reacting molecule remains to be determined, we have shown that
its aggregation in PBs is modulated similarly to most PB
components, as pharmacological or siRNA-mediated PB disrup-
tion dramatically affects the detection of Pab 1801 puncta. This
elusive molecule that shares an epitope with human p53 is
conserved in human and rodents, and our studies suggest that is
distinct from Dcp1a, Dcp1b, Dcp2, Rck/p54, Xrn1, 4ET and
Hedls. PBs are complex supramolecular aggregates of RNPs, and
their protein composition is not completely known. Currently,
hundreds of proteins with different functions are known to be
recruited to PBs [11,20], and novel PB components are expected
to be identified with the help of high performance approaches that
are underway. This information will be highly valuable for the
identification of the PB component(s) recognized by Pab 1801.
The Pab 1801 monoclonal antibody was raised against a
recombinant polypeptide including amino acids 32 to 393 of
human p53, and the epitope spans from amino acids 32 and 79
[18]. Later on, Soussi and col. [19] mapped the epitope to a
fragment from amino acid 46 to 55, with the sequence
SPDDIEQWFT. A survey of the most important PB components
indicates that no significant homology occurs between this 10
amino acid sequence and Dcp1a, Dcp1b, Dcp2, Hedls, Rck/p54,
4ET, Xrn1, GW182, or Lsm1. However, protein conformation
may affect antibody binding, and the epitope may be split in more
than one peptide segments. Interestingly, the PB component Edc3
includes a conserved 4 amino acid sequence (DDIE), which is not
present in Drosophila Edc3 and that may potentially be
recognized in the context of the full molecule, where additional
contact sites would be provided by amino acids somewhere else in
the molecule. This remains to be investigated. In contrast, post-
translational modifications are unlikely to be involved in the cross-
reactivity reported here, given that the immunogen used for the
preparation of this monoclonal antibody was a recombinant
polypeptide.
The cytoplasmic localization of p53 is an emerging aspect in the
cell biology of this important transcriptional regulator [2]. Having
reliable tools is critical to assess p53 localization to the
mitochondria, cytosol or cytosolic aggregates, three major
cytoplasmic compartments where p53 is located upon different
conditions, and with different consequences in cell homeostasis
[1,2]. The cross-reactivity of the Pab 1801 antibody with PBs was
previously overlooked, and this antibody was used to conclude the
occurrence of p53 cytosolic aggregates under a variety of
conditions [6,7]. Our observations imply that imaging of
cytoplasmic p53 with the Pab 1801 requires careful interpretation
and controls.
Figure 7. Pab 1801 puncta and PBs are simultaneously induced by different strategies. A, B, U2OS cells were treated with two different
combinations of arsenite and puromycin: 250 mM arsenite +100 mg/ml puromycin (16induction) and 500 mM arsenite +250 mg/ml puromycin (26
induction). A, The average number of PBs per cell increased from 4 in control cells to 14 in treated cells, as evaluated in 100 cells from duplicate
experiments for each treatment. Induced PBs were stained with the Pab 1801 in all cases. An example of the 26induction is shown in Ars+Puro panel.
B, the size of Dcp1a-foci and Pab 1801 foci increased at the same rate and in a dose-dependent manner. Median values of more than 100 foci size for
each treatment were plotted. C, overexpression of the translational repressor Smaug 1 also provoked 1801 foci induction. U2OS cells were transfected
with Smaug 1-ECFP and number of foci per cell and foci size were analized in transfected (T) and neighbouring non-transfected cells (NT). The
average number of PBs per cell increased from 5 in non-transfected cells to 55 in transfected cells, as evaluated in 100 hundred cells of each
condition. In all cases PBs were stained with the 1801 antibody. The foci size increased more than twice, as evaluated for both 1801 and Rck/p54 in
200 non-transfected foci and 750 Smaug1-ECFP transfected foci. Bars, 10 mm.
doi:10.1371/journal.pone.0036447.g007
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Ethic Statement
All the work involving animals was performed at Instituto
Leloir where NIH regulations are followed at the animal facility
(Assurance number A5168-01). The protocol was specifically
approved by the Institutional Animal Care and Use Committee
of the Fundacio ´n Instituto Leloir (IACUC-FIL, Protocol 2009 08
26GB) according to the Principles for Biomedical Research
involving animals of the Council for International Organizations
for Medical Sciences and provisions stated in the Guide for the
Care and Use of Laboratory Animals.
Cells and Drug Treatments
The human osteosarcoma cell line U2OS, the human
fibroblast-like fetal lung cell line WI 38, the human neuroblas-
toma SK-N-SH cell line, the human non-small cell lung
carcinoma cell line H1299 were from the ATCC (American
Tissue Culture Collection). The human colonic epithelial
HCT116 p53+/+ and 2/2 cells were originally obtained from
Bert Volgestein laboratory [16]. All cell lines were maintained in
DMEN or McCoy medium supplemented with 10% fetal bovine
serum (Natocor, Co ´rdoba, Argentina), penicillin and streptomy-
cin (Sigma). Schneider S2R+ cells from the Drosophila Genomic
Resource Center (Indiana University, Bloomington, IN) were
grown in M3+ BYPE supplemented as above [29,31]. Hippo-
campal cultures were prepared as described previously [27].
Briefly, hippocampi were dissected from Sprague Dawley rats at
embryonic day 18 and digested with trypsin. Cells were seeded
on poly-d-lysine (Sigma-Aldrich)-coated glass coverslips. Cultures
were maintained in Neurobasal medium (NB; Invitrogen)
supplemented with B27 (Invitrogen) and glutamine (complete
NB; Invitrogen) at 5% CO2.
When using chemicals, stock solutions were always diluted into
conditioned medium. The final concentrations of the compounds
used were: thapsigargin, 1 mM (SIGMA); cycloheximide, 250 mg/
ml (SIGMA); puromycin, 100 and 250 mg/ml (SIGMA); arsenite,
250 and 500 mM (SIGMA); daunorubicin, 0.22 mM (Oncogene
Research Products); actinomycin D, 5 nM (Calbiochem).
Figure 8. Commercial and domestic sources of Pab 1801 behave similarly. A, U2OS p53+/+ and H1299 p532/2 were simultaneously
stained with Dpc1a, Rck/p54 and Pab 1801 from a commercial source (left panels) or from domestic preparations of hybridome supernantant (right
panels). B, HCT 116 p53+/+ and HCT116 p532/2 were simultaneously stained with Hedls and Pab 1801 from the same two sources. The strong
pattern of Pab 1801 puncta was similar for both commercial and domestic sources of the Pab 1801 in p53+/+ and p532/2 cell lines. Bars, whole cells,
10 mm; magnifications, 1 mm.
doi:10.1371/journal.pone.0036447.g008
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Smaug1-ECFP construct was previously described [26,27].
Cell lines were transfected with either Lipofectamine 2000
Transfection Reagent (Invitrogen) or Jet Prime (Polyplus
Transfection) following manufacturer’s instructions. Immunoflu-
orescence was performed as previously described [22,23,29] Mild
non-aqueous fixation with methanol-acetone 1:1 was performed
3 minutes at room temperature [6] and strong non-aqueous
fixation was done with the same solution for 20 minutes at
220uC. In both types of treatments immunofluorescence was
done without permeabilization. Permeabilization of live cells with
0.1% of the non-ionic detergent Triton X-100 in CSKB (CSK
buffer) was performed during 5 and 10 minutes prior to fixation
in PFA 4% [22,29]. When indicated, treatment with RNase A
(Sigma) (100 mg/ml in CSKB) was performed for 5 minutes after
5 minutes of live permeabilization with 0.1% TX100 in CSKB.
Monoclonal Pab 1801 was obtained by immunization with a
recombinant peptide of amino acids 32 to 393 of human p53
[18]. Two different sources were used: hybridome’s supernatant
without dilution was used in figures 1, 2, 3, 4, 5, 6, 7, 8, 9, 10,
11 and commercial Pab 1801 diluted 1:100 (sc-98, Santa Cruz,
CA, USA) was used in figure 8 and figure S1. The rest of
monoclonal anti p53 antibodies derived from hybridome’s
supernatant and used without dilution were the following: Pab
DO1, prepared using recombinant wt human p53 (recognizes
amino acids 11 to 25) [33]. Pab 240, generated against a fusion
protein containing amino acids 156–214 of mammalian p53 [34].
Pab 421, raised against mouse p53 protein (recognizes amino
acids 371–380) [35]. Primary antibodies were diluted as follows:
polyclonal rabbit anti-p53 FL 393 (Santa Cruz, CA, USA),
1:100; monoclonal IgG2a anti Dcp1a (Abnova Corporation,
Taiwan), 1:1000; polyclonal rabbit anti-Hedls and anti Rck/p54
(Bethyl; TX, USA), 1:500; polyclonal anti-Staufen [22], 1:400;
goat anti-TIA1 (Santa Cruz, CA, USA), 1:100. Secondary
antibodies coupled to Alexa 488, Alexa 555 or Alexa 666, used
at 1:500–1:1000, were from Molecular Probes (Invitrogen
Corporation, Carlsbad CA, USA); or coupled to Cy2, Cy3 or
Figure 9. Different procedures give the same immunostaining
pattern of Pab 1801. U2OS cells were treated as indicated and
immunostained with Pab 1801 and Hedls. A, U2OS cells were fixed as
usual in 4% PFA. B, live U2OS cells were treated with methanol-acetone
during 3 minutes at room temperature (mild non-aq). C, live U2OS cells
were treated with methanol-acetone during 20 minutes at 220uC
(strong non-aq). D, live U2OS cells were permeabilized with 0.1% Triton
X-100 for 10 minutes prior to fixation in PFA 4%. Nuclear staining with
Pab 1801 looks stronger than in control cells. None of these treatments
affected the cross-reaction of the Pab 1801 with PBs. Bars, whole cells,
10 mm; magnifications, 1 mm.
doi:10.1371/journal.pone.0036447.g009
Figure 10. RNase treatment or knockdown of specific PB
components provokes the simultaneous dissolution of PBs and
Pab 1801 puncta. A, live U2OS cells were permeabilized with 0.1%
TX100 for five minutes and then exposed to CSKB without (Control) or
with 100 mg/ml of RNase (RNase) for additional 5 minutes. The
percentage of cells with PBs simultaneous stained with Dcp1a and
Pab 1801 was evaluated in 100 cells from duplicate experiments for
each treatment and diminished from 75% in control cells to 40% in
RNAse-treated cells. The remaining Pab 1801 foci have less than half of
the size of control cells. B, U2OS and SK-N-SH cells were treated with
specific siRNAs against the PB components Hedls, Rck/p54 or 4ET, and
stained with the indicated antibodies. The Pab 1801 puncta vanished
when PB are disrupted. The proportion of cells with foci is indicated, as
evaluated in 100 cells from duplicate experiments for each treatment.
As before (Figures 4, 5 and 6), all puncta were double stained for each
pair of antibodies and single-stained foci were not present in any of the
treatments. Bar, 10 mm.
doi:10.1371/journal.pone.0036447.g010
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Laboratories (West Grove, PA, USA). In all the immunostainings
were monoclonal Pab 1801 (IgG1) was combined with mono-
clonal anti Dcp1a (IgG2a), anti isotypes coupled to A 488 or
A555 from Molecular Probes (Invitrogen Corporation, Carlsbad
CA, USA) were used at 1:500 (Figures 4, 5, 7A, 8, 10A and B,
11B and C).
siRNA-treatment
U2OS cells were treated with a non-targeting siRNA (siNT) 59-
UAGCGACUAAACACAUCAA, a siRNA anti-Hedls (siHedls,
Cat. Num. 004397, Dharmacon); anti-Rck/p54 (siRck/p54, Cat.
Num. 0143295, Dharmacon); or against 4ET (59GAACAA-
GAUUAUCGACCUA) [36] used at 50 nM during 72 hs. Jet
Prime (Polyplus Transfection) was used as transfection reagent and
manufacturer instructions were followed.
Imaging
Images were acquired in a PASCAL-LSM or a LSM510 Meta
confocal microscopes (Carl Zeiss, Oberkochen, Germany), using
C-Apochromat 406/1.2 W Corr or 636/1.2 W Corr - water
immersion objectives for the LSM, and a EC ‘‘Plan-Neofluor’’
406/1.30 Oil or Plan-Apochromat 636/1,4 Oil for the LSM510
Meta. Images were acquired with Zeiss LSM software, and pixel
intensity was always lower that 250, being 255 saturating levels.
Equipment adjustment was assessed by using 1 mm FocalCheck
fluorescent microspheres (Molecular Probes). No filters or gamma
adjustment were used previous to the analysis of number of cells
with foci or foci size using the ImageJ software.
Western Blot
Western blotting was performed by standard procedures using
PVDF membranes (Immobilon-P polyvinylidene difluoride, Milli-
pore, Bedford, MA), LumiGlo (Cell Signaling) and Hyperfilm
(Amersham Biosciences). Hybridome supernatant from Pab DO1
was used diluted in 5% milk/PBST. Anti b-actin (SIGMA) was
diluted 1:5,000. For semi-quantitative analysis, autoradiographs
were scanned and signal intensity evaluated with the ImageJ
software.
Supporting Information
Figure S1 Western blot with the Pab 1801 gives multiple
bands. Whole lysates from U2OS, H1299, HCT166 p53+/+ and
HCT p532/2 cells were immunoblotted with commercial and
domestic Pab 1801. p53 is present in p53+/+ cells but not in
p532/2 cells. Additional bands at around 75, 60, 36, 33 and
30 kDa were detected.
(TIF)
Figure S2 The Pab 1801 does not cross react with
Dcp1a, Dcp1b, Rck/p54 or Dcp2. U2OS cells were
transfected with human Dcp1a (A); Dcp1b (B); Rck/p54 (C) or
Dcp2 (D) fused to FLAG, and stained with an antibody against
FLAG (see supplementary Material and Methods). Simultaneous-
ly, cells were stained with the Pab 1801. Representative transfected
cells for each construct are shown in the left panels, and examples
of neighbouring non-transfected cells for each case are shown in
the right. None of the overexpressed PB components increased the
signal intensity of the Pab 1801 staining. Bars, 10 mm.
(TIF)
Supporting Information S1 Supporting information cor-
responding to transient-transfection approach to ruled
out cross-reactivity of the Pab 1801 with PB components
Dcp1a, Dcp1b, Rck/p54, Dcp2, and 4ET [37].
(DOCX)
Supporting Materials and Methods S1 Supporting mate-
rials and methods corresponding to transient-transfec-
tion of the PB components Dcp1a, Dcp1b, Rck/p54,
Dcp2, and 4ET [37].
(DOCX)
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Figure 11. The Pab 1801 does not recognize Drosophila PBs,
and stains a subset of PBs in rat neurons. A, S2R+ cells were
immunostained with the Pab 1801 and an antibody against Ge-1/Hedls.
No signal of the Pab 1801 was observed. Bars, 10 mm. B, rat primary
neurons were simultaneously stained with Pab 1801, Hedls and Tubulin
b III. Pab 1801 puncta and Hedls colocalize partially. Bars, whole
neurons, 10 mm; dendrites, 1 mm. C, representative dendritic fragments
showing immunostaining against Pab 1801 and the PB components
Xrn1, Dcp1a and Rck/p54. As above, Pab DO1 yielded no signal. Bars,
1 mm.
doi:10.1371/journal.pone.0036447.g011
Shared Immunoreactivity between p53 and PBs
PLoS ONE | www.plosone.org 10 May 2012 | Volume 7 | Issue 5 | e36447Author Contributions
Conceived and designed the experiments: MGT GLB. Performed the
experiments: MGT LL MP. Analyzed the data: MGT LL MP VG GLB.
Contributed reagents/materials/analysis tools: MGT VG GLB. Wrote the
paper: MGT VG GLB.
References
1. Brady CA, Attardi LD (2010) p53 at a glance. J Cell Sci 123: 2527–2532.
2. Green DR, Kroemer G (2009) Cytoplasmic functions of the tumour suppressor
p53. Nature 458: 1127–1130.
3. Wang F, Fu X, Chen X, Zhao Y (2010) Mitochondrial uncoupling inhibits p53
mitochondrial translocation in TPA-challenged skin epidermal JB6 cells. PLoS
One 5: e13459.
4. Moll UM, Riou G, Levine AJ (1992) Two distinct mechanisms alter p53 in
breast cancer: mutation and nuclear exclusion. Proc Natl Acad Sci U S A 89:
7262–7266.
5. Moll UM, LaQuaglia M, Benard J, Riou G (1995) Wild-type p53 protein
undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not
in differentiated tumors. Proc Natl Acad Sci U S A 92: 4407–4411.
6. Moll UM, Ostermeyer AG, Haladay R, Winkfield B, Frazier M, et al. (1996)
Cytoplasmic sequestration of wild-type p53 protein impairs the G1 checkpoint
after DNA damage. Mol Cell Biol 16: 1126–1137.
7. Ostermeyer AG, Runko E, Winkfield B, Ahn B, Moll UM (1996) Cytoplasmi-
cally sequestered wild-type p53 protein in neuroblastoma is relocated to the
nucleus by a C-terminal peptide. Proc Natl Acad Sci U S A 93: 15190–15194.
8. Nikolaev AY, Li M, Puskas N, Qin J, Gu W (2003) Parc: a cytoplasmic anchor
for p53. Cell 112: 29–40.
9. Qu L, Huang S, Baltzis D, Rivas-Estilla AM, Pluquet O, et al. (2004)
Endoplasmic reticulum stress induces p53 cytoplasmic localization and prevents
p53-dependent apoptosis by a pathway involving glycogen synthase kinase-
3beta. Genes Dev 18: 261–277.
10. Becker K, Marchenko ND, Maurice M, Moll UM (2007) Hyperubiquitylation of
wild-type p53 contributes to cytoplasmic sequestration in neuroblastoma. Cell
Death Differ 14: 1350–1360.
11. Thomas MG, Loschi M, Desbats MA, Boccaccio GL (2011) RNA granules: the
good, the bad and the ugly. Cell Signal 23: 324–334.
12. Kaul SC, Aida S, Yaguchi T, Kaur K, Wadhwa R (2005) Activation of wild type
p53 function by its mortalin-binding, cytoplasmically localizing carboxyl
terminus peptides. J Biol Chem 280: 39373–39379.
13. Kruse JP, Gu W (2009) MSL2 Promotes Mdm2-independent Cytoplasmic
Localization of p53. J Biol Chem 284: 3250–3263.
14. Mallette FA, Gaumont-Leclerc MF, Ferbeyre G (2007) The DNA damage
signaling pathway is a critical mediator of oncogene-induced senescence. Genes
Dev 21: 43–48.
15. Ashcroft M, Taya Y, Vousden KH (2000) Stress signals utilize multiple pathways
to stabilize p53. Mol Cell Biol 20: 3224–3233.
16. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, et al. (1998)
Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science
282: 1497–1501.
17. Lin DL, Chang C (1996) p53 is a mediator for radiation-repressed human TR2
orphan receptor expression in MCF-7 cells, a new pathway from tumor
suppressor to member of the steroid receptor superfamily. J Biol Chem 271:
14649–14652.
18. Banks L, Matlashewski G, Crawford L (1986) Isolation of human-p53-specific
monoclonal antibodies and their use in the studies of human p53 expression.
Eur J Biochem 159: 529–534.
19. Legros Y, Lafon C, Soussi T (1994) Linear antigenic sites defined by the B-cell
response to human p53 are localized predominantly in the amino and carboxy-
termini of the protein. Oncogene 9: 2071–2076.
20. Buchan JR, Parker R (2009) Eukaryotic stress granules: the ins and outs of
translation. Mol Cell 36: 932–941.
21. Erickson SL, Lykke-Andersen J (2011) Cytoplasmic mRNP granules at a glance.
J Cell Sci 124: 293–297.
22. Thomas MG, Martinez Tosar LJ, Loschi M, Pasquini JM, Correale J, et al.
(2005) Staufen recruitment into stress granules does not affect early mRNA
transport in oligodendrocytes. Mol Biol Cell 16: 405–420.
23. Thomas MG, Tosar LJ, Desbats MA, Leishman CC, Boccaccio GL (2009)
Mammalian Staufen 1 is recruited to stress granules and impairs their assembly.
J Cell Sci 122: 563–573.
24. Rzeczkowski K, Beuerlein K, Muller H, Dittrich-Breiholz O, Schneider H, et al.
(2011) c-Jun N-terminal kinase phosphorylates DCP1a to control formation of P
bodies. J Cell Biol 194: 581–596.
25. Takahashi S, Sakurai K, Ebihara A, Kajiho H, Saito K, et al. (2011) RhoA
activation participates in rearrangement of processing bodies and release of
nucleated AU-rich mRNAs. Nucleic Acids Res 39: 3446–3457.
26. Baez MV, Boccaccio GL (2005) Mammalian Smaug is a translational repressor
that forms cytoplasmic foci similar to stress granules. J Biol Chem 280:
43131–43140.
27. Baez MV, Luchelli L, Maschi D, Habif M, Pascual M, et al. (2011) Smaug1
mRNA-silencing foci respond to NMDA and modulate synapse formation. J Cell
Biol 195: 1141–1157.
28. Wilczynska A, Aigueperse C, Kress M, Dautry F, Weil D (2005) The
translational regulator CPEB1 provides a link between dcp1 bodies and stress
granules. J Cell Sci 118: 981–992.
29. Loschi M, Leishman CC, Berardone N, Boccaccio GL (2009) Dynein and
kinesin regulate stress-granule and P-body dynamics. J Cell Sci 122: 3973–3982.
30. Sen GL, Blau HM (2005) Argonaute 2/RISC resides in sites of mammalian
mRNA decay known as cytoplasmic bodies. Nat Cell Biol 7: 633–636.
31. Dekanty A, Romero NM, Bertolin AP, Thomas MG, Leishman CC, et al. (2010)
Drosophila genome-wide RNAi screen identifies multiple regulators of HIF-
dependent transcription in hypoxia. PLoS Genet 6: e1000994.
32. Cougot N, Bhattacharyya SN, Tapia-Arancibia L, Bordonne R, Filipowicz W,
et al. (2008) Dendrites of mammalian neurons contain specialized P-body-like
structures that respond to neuronal activation. J Neurosci 28: 13793–13804.
33. Vojtesek B, Bartek J, Midgley CA, Lane DP (1992) An immunochemical analysis
of the human nuclear phosphoprotein p53. New monoclonal antibodies and
epitope mapping using recombinant p53. J Immunol Methods 151: 237–244.
34. Stephen CW, Lane DP (1992) Mutant conformation of p53. Precise epitope
mapping using a filamentous phage epitope library. J Mol Biol 225: 577–583.
35. Wade-Evans A, Jenkins JR (1985) Precise epitope mapping of the murine
transformation-associated protein, p53. EMBO J 4: 699–706.
36. Ferraiuolo MA, Basak S, Dostie J, Murray EL, Schoenberg DR, et al. (2005) A
role for the eIF4E-binding protein 4E-T in P-body formation and mRNA decay.
J Cell Biol 170: 913–924.
37. Fenger-Gron M, Fillman C, Norrild B, Lykke-Andersen J (2005) Multiple
processing body factors and the ARE binding protein TTP activate mRNA
decapping. Mol Cell 20: 905–915.
Shared Immunoreactivity between p53 and PBs
PLoS ONE | www.plosone.org 11 May 2012 | Volume 7 | Issue 5 | e36447